Sarepta Therapeutics, Inc. (SRPT) Fair Value 2026

SRPT · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.1 /10

32 fundamental signals · 3 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-28, Sarepta Therapeutics, Inc. (SRPT) trades at $20.86, versus a $16.97 median fair value across its 3 active models — 18.7% below the current price. QOC: 7.1/10. Value Trap Risk: 13/100 (SAFE). 3/13 models active.

Key Facts

Ticker
SRPT
Price
$20.86
Quality Score
7.1/10
Value Trap Risk
13/100
Models Active
3/13
Last Updated
Strength: PWERM suggests +7.0% upside with 33% confidence
Risk: Majority of models suggest overvaluation

Is Sarepta Therapeutics, Inc. (SRPT) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Sarepta Therapeutics, Inc. (SRPT) appears overvalued as of : the median of 3 independent fair value estimates is $16.97, 18.7% below the current price of $20.86. Estimates range from $11.32 to $22.33. SRPT scores 7.1/10 on fundamental quality and 13/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. SRPT’s -18.7% gap is narrower than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Sarepta Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give SRPT?

3 Intrinsic Value Models vs. Current Price ($20.86)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $11.32 -45.8%
Option-Based · Medium Conviction
 $22.33 +7.0%
Relative · Low Conviction
 $16.97 -18.7%

All Models Active

All 3 models are displayed above.

What Is SRPT's Fair Value Range?

Spread across 3 independent models · $11.32 to $22.33

CirclFi's 3 active models place Sarepta Therapeutics, Inc. (SRPT) between $11.32 and $22.33 per share, a spread of 65% of the median. The median of that range — $16.97 — is the fair value CirclFi publishes for SRPT, against a current price of $20.86.

Low · Regime CrossHigh · PWERM
$11.32median $16.97$22.33
Where the range comes from
Most bearish modelRegime Cross-Sectional$11.32
Most bullish modelPWERM$22.33
Model agreement1 bullish · 2 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on SRPT, not a CirclFi price target. How each model works →

What Is Sarepta Therapeutics, Inc. (SRPT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Sarepta Therapeutics, Inc. at its current price of $20.86. The median intrinsic value is estimated at $16.97 (-18.7% vs price), with 2 models flagging overvaluation risk. Model dispersion is worth noting: PWERM targets $22.33 (+7.0%), versus Regime Cross at $11.32 (-45.8%). This +52.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SRPT?

3 of 13 models are currently active for SRPT. Of these, 1 model suggests upside while 2 models suggest overvaluation. Taken together, their median fair value for SRPT is $16.97 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does SRPT Rank in Biotechnology?

Among 625 Biotechnology stocks, SRPT ranks #42 by Quality of Company score. CirclFi's QOC score of 7.1/10 evaluates 32 fundamental signals. A score of 7.1 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Sarepta Therapeutics, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating SRPT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SRPT a Value Trap?

CirclFi's Value Trap algorithm assigns SRPT a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Sarepta Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Sarepta Therapeutics, Inc.'s fundamental quality profile registers 7.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +52.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SRPT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SRPT's 3 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sarepta Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ARCTArcturus Therapeutics Holdings Inc.QOC 7.2ABUSArbutus Biopharma CorporationQOC 7.1ARVNArvinas, Inc.QOC 7.2URGNUroGen Pharma Ltd.QOC 7.1TLXTelix Pharmaceuticals LimitedQOC 7.2MRNAModerna, Inc.QOC 7.0AUTLAutolus Therapeutics plcQOC 5.6PVCTProvectus Biopharmaceuticals, Inc.QOC 4.9ARTLArtelo Biosciences, Inc.QOC 4.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ARCT · ABUS · ARVN · URGN · TLX · MRNA · AUTL · PVCT · ARTL · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SRPT?

6 companies across all industries closest to SRPT’s Quality of Company score of 7.1/10.

SANBanco Santander, S.A.QOC 7.1SDGRSchrödinger, Inc.QOC 7.1GGBGerdau S.A.QOC 7.1CNRCore Natural Resources, Inc.QOC 7.1CRWSCrown Crafts, Inc.QOC 7.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SAN · SDGR · GGB · CNR · CRWS · NVDA

Where Does SRPT Sit in CirclFi's Biotechnology Rankings?

SRPT is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Sarepta Therapeutics, Inc.’s Valuation?

What is Sarepta Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Sarepta Therapeutics, Inc. (SRPT)'s intrinsic value at $16.97 — the median of 3 independent model estimates as of 2026-08-28, ranging from $11.32 to $22.33. The Quality of Company score is 7.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SRPT overvalued or undervalued right now?

At $20.86, 1 of 3 active models suggest SRPT may be undervalued, while 2 indicate potential overvaluation. The median of all 3 fair value estimates is $16.97, 18.7% below the current price of $20.86 — a consensus view that SRPT is overvalued. The assessment depends on which methodology best fits Sarepta Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 7.1 mean for SRPT?

Sarepta Therapeutics, Inc.'s QOC of 7.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SRPT?

CirclFi analyzes SRPT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on SRPT?

Of the 3 models currently active on SRPT, PWERM is the most bullish at $22.33 per share, and Regime Cross-Sectional is the most bearish at $11.32. CirclFi's published fair value for SRPT is the median of that range, $16.97, not either extreme. The gap between the two ends equals 65% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is SRPT a value trap in 2026?

Sarepta Therapeutics, Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Sarepta Therapeutics, Inc. (SRPT) has a median fair value of $16.97 — 18.7% below the current price of $20.86 — as of 2026-08-28.” Source: circlfi.com/stock/SRPT/ · Methodology
Primary sources for this SRPT valuation
  • Financial statements: Sarepta Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000873303) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SRPT as of ; valuations recomputed .